Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease-Reference-Cited by-同舟云学术

Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease

Published:2020-10-13 Issue:11 Volume:16 Page:1483-1492
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Wessels Alette M.¹,Lines Christopher²,Stern Robert A.³,Kost James²,Voss Tiffini²,Mozley Lyn Harper²,Furtek Christine²,Mukai Yuki²,Aisen Paul S.⁴,Cummings Jeffrey L.⁵,Tariot Pierre N.⁶,Vellas Bruno⁷,Dupre Nicole²,Randolph Christopher⁸,Michelson David²,Andersen Scott W.¹,Shering Craig⁹,Sims John R.¹,Egan Michael F.²

Affiliation:

1. Eli Lilly and Company Indianapolis Indiana USA

2. Merck & Co., Inc. Kenilworth New Jersey USA

3. Alzheimer's Disease Center Boston University School of Medicine Boston Massachusetts USA

4. University of Southern California San Diego California USA

5. Department of Brain Health School of Integrated Health Sciences University of Nevada Las Vegas (UNLV) and Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas Nevada USA

6. Banner Alzheimer's Institute Phoenix Arizona USA

7. Gerontopole INSERM U1027 Alzheimer's Disease Research and Clinical Center Toulouse University Hospital Toulouse France

8. MedAvante‐ProPhase, Hamilton, NJ and Department of Neurology Loyola University Medical Center Maywood Illinois USA

9. AstraZeneca Boston Massachusetts USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12164

Reference23 articles.

1. The amyloid hypothesis of Alzheimer's disease at 25 years

2. Targeting the β secretase BACE1 for Alzheimer's disease therapy

3. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

4. AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer’s Disease

5. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The novel role of Kallistatin in linking metabolic syndromes and cognitive memory deterioration by inducing amyloid-β plaques accumulation and tau protein hyperphosphorylation;2024-08-13

2. The novel role of Kallistatin in linking metabolic syndromes and cognitive memory deterioration by inducing amyloid-β plaques accumulation and tau protein hyperphosphorylation;2024-08-13

3. Enhanced phagocytosis associated with multinucleated microglia via Pyk2 inhibition in an acute β-amyloid infusion model;Journal of Neuroinflammation;2024-08-06

4. Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease model mice;Nature Neuroscience;2024-08-05

5. Beyond Amyloid-β: Reevaluating Its Physiological Role to Find Safe Therapies Against Alzheimer’s Disease;Journal of Alzheimer's Disease;2024-07-30